Enzalutamide Monograph for Professionals - Drugs.com
网页2024年8月10日 · Metabolized by CYP2C8 and CYP3A4; formation of major active metabolite (N -desmethylenzalutamide) is mediated by CYP2C8. Enzalutamide is a strong inducer of CYP3A4 and a moderate inducer of CYP2C9 and CYP2C19 in vivo. Induces CYP2B6 in vitro. Does not induce CYP1A2 at clinically relevant concentrations.
Colchicine Monograph for Professionals - Drugs.com
网页2024年4月10日 · Oral. Use of colchicine for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares. Mild to moderate renal impairment (Cl cr 50–80 or 30–50 mL/minute, respectively): Dosage adjustment is not needed, but monitor for adverse effects.
Apixaban Monograph for Professionals - Drugs.com
网页Drugs Affecting P-gp and CYP3A4. Combined P-gp and CYP3A4 inhibitors: Possible increased apixaban exposure, which may increase risk of bleeding. Reduce dosage if used concomitantly with a potent dual inhibitor of P-gp and CYP3A4; avoid use if patient already receiving reduced dosage.
Mirtazapine Monograph for Professionals - Drugs.com
网页Metabolized by CYP2D6, CYP3A4, and CYP1A2; not a potent inhibitor of CYP2D6, CYP3A4, and CYP1A2. Drugs Affecting Hepatic Microsomal Enzymes. Potential pharmacokinetic interaction (decreased mirtazapine metabolism) with inhibitors of CYP2D6, CYP3A4, or CYP1A2.
Rimegepant Monograph for Professionals - Drugs.com
网页2024年3月15日 · Potent CYP3A4 Inhibitors: Possible substantially increased rimegepant exposure. Avoid concomitant use. Moderate CYP3A4 Inhibitors: Possible increased rimegepant exposure; less than twofold increase expected. In patients receiving a moderate CYP3A4 inhibitor, do not administer multiple doses of rimegepant within 48 hours of …
Lurasidone Monograph for Professionals - Drugs.com
网页2024年2月21日 · Potent CYP3A4 inducers: Potential pharmacokinetic interaction. Concomitant use contraindicated. Moderate CYP3A4 inducers: Potential pharmacokinetic interaction. May need to increase lurasidone dosage after chronic therapy (i.e., ≥7 days) with the CYP3A4 inducer.
Drug Interactions with Grapefruit Juice - Drugs.com
网页2024年3月10日 · Grapefruit juice can even interact with some over-the-counter (OTC) drugs. Examples of common medications that may interact with grapefruit juice include: Certain statin drugs used to lower cholesterol such as atorvastatin (Lipitor), lovastatin, simvastatin (Zocor). Loratadine (Claritin Allergy), a common OTC non-sedating antihistamine.
Mavacamten Monograph for Professionals - Drugs.com
网页2024年2月10日 · Mavacamten primarily metabolized by CYP2C19 and CYP3A4. Concomitant use with other drugs that interact with these enzymes may lead to life-threatening interactions such as heart failure or loss of effectiveness. Advise patients of potential drug interactions and to report use of all prescription and …
Lumateperone Monograph for Professionals - Drugs.com
网页Concomitant administration with strong CYP3A4 inhibitors: recommended dosage of lumateperone is 10.5 mg once daily. Concomitant administration with moderate CYP3A4 inhibitors: recommended dosage of lumateperone is 21 mg once daily. Special Populations Hepatic Impairment. Mild hepatic impairment (Child-Pugh class A): …
Caplyta Dosage Guide - Drugs.com
网页2023年6月29日 · Coadministration with Strong CYP3A4 Inhibitors. The recommended dosage for patients receiving strong CYP3A4 inhibitors is CAPLYTA 10.5 mg once daily [see Drug Interactions (7.1)]. Coadministration with Moderate CYP3A4 Inhibitors. The recommended dosage for patients receiving moderate CYP3A4 inhibitors is CAPLYTA 21 mg once daily [see Drug ...